Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Resubmission Acknowledgment Letter - Isoplate Solution

DEPARTMENT OF HEALTH & HUMAN SERVICES                                                     Public Health Service

                                                                                                                            Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448


Our STN: NDA BN090067
B. Braun Medical, Inc.
Attention:  Ms. Rebecca Stolarick
901 Macron Boulevard
Allentown, PA 18109
Dear Ms. Stolarick
We acknowledge receipt on January 4, 2013, of your January 4, 2013, resubmission to your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Isoplate Solution, magnesium chloride USP 30mg/100mL.
We consider this a complete, class 1 response to our May 8, 2012, action letter. Therefore, the goal date is March 5, 2013.
If you have any questions, call Sonday L. Kelly, MS, RAC, Regulatory Project Manager, at (301) 827-6162.
Iliana Valencia, MS
Chief, Regulatory Project Management Branch
Division of Blood Applications
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 04/03/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English